Browse News
Filter News
Found 288 articles
-
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
4/2/2024
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) today announced completion of the dose escalation part of a Phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer (“NSCLC”) that cannot be treated by surgery (“inoperable”), and has come back (“recurrent”), whom have previously been treated with definitive radiation therapy and are amenable to re-irradiation.
-
Nanobiotix to Present at Upcoming Investor Conferences in March 2024
3/6/2024
NANOBIOTIX announced that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference.
-
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
1/31/2024
NANOBIOTIX announced that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.
-
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
1/29/2024
NANOBIOTIX today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company.
-
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
1/17/2024
INVO and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024.
-
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
12/26/2023
NANOBIOTIX announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand.
-
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
12/26/2023
LianBio announced that the company has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand.
-
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
12/20/2023
Saint-Herblain, December 20, 2023 – Valneva SE, a specialty vaccine company, announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting held on December 20, 2023.
-
Under an agreement with Johnson & Johnson’s Actelion Pharmaceuticals, the rights to the multiple sclerosis drug Ponvory in the U.S. and Canada will be transferred to Vanda Pharmaceuticals.
-
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
12/4/2023
NANOBIOTIX announces the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares, for an aggregate amount of $4.8 million, equivalent to €4.6 million, following the approval by the French Ministry of Economy of JJDC Remaining Placement on November 22, 2023, in accordance with the French foreign investment control rules2.
-
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
11/13/2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.
-
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
11/9/2023
NANOBIOTIX announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the US market.
-
NANOBIOTIX Announces Closing of Global Offering - November 07, 2023
11/7/2023
NANOBIOTIX announces the closing of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares in the form of American Depositary Shares.
-
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
11/1/2023
NANOBIOTIX announces the launch, subject to market and other conditions, of an approximately $30.0 million global follow-on offering reserved to specified categories of investors consisting of an offering of its American Depositary Shares.
-
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
10/23/2023
NANOBIOTIX announced updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology.
-
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free
10/4/2023
NANOBIOTIX announced the final readout on primary endpoints from Study 102 Dose Expansion—the expansion part of a Phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for patients with locally advanced head and neck cancer.
-
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
9/29/2023
NANOBIOTIX announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with locally advanced head and neck cancer—at the 65th Annual Meeting of the American Society for Radiation Oncology.
-
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
9/28/2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new clinical data from a Phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with pancreatic ductal adenocarcinoma (PDAC).
-
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
9/26/2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2023.
-
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
9/19/2023
NANOBIOTIX announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market.